View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsCOVA Acquisition 과거 순이익 실적과거 기준 점검 1/6핵심 정보8.96%순이익 성장률n/a주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Sep 2022최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.공시 • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.공시 • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.공시 • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.공시 • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.매출 및 비용 세부 내역COVA Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:COVA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 22096030 Jun 220145031 Mar 220222031 Dec 2101220양질의 수익: COVA는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 지난 1년 동안 COVA의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: COVA은 상장된 지 3년이 되지 않아 지난 5년간 전년 대비 수익 증가율이 긍정적인지 확인할 수 없습니다.성장 가속화: COVA은 상장된 지 3년이 되지 않아 지난 해 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: COVA의 지난 1년 수익 증가율(9%)은 Capital Markets 업계 평균(37.2%)을 능가하지 못했습니다.자기자본이익률높은 ROE: COVA의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/21 20:10종가2022/12/20 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스COVA Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.
공시 • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.
공시 • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.
공시 • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.
공시 • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.